ArticleFrontiers in oncology2026
Dynamic white blood cell kinetics enable early risk stratification of differentiation syndrome in low- and intermediate-risk acute promyelocytic leukemia.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiation syndrome (DS) is a potentially life-threatening complication during induction therapy for acute promyelocytic leukemia (APL). Previous studies have linked white blood cell (WBC) elevation with DS development; however, conventional WBC-based assessment mainly relies on peak values and does not adequately reflect the dynamic pattern or timing of WBC changes. We aimed to develop and internally validate an early warning model for DS based on early WBC kinetics during arsenic trioxide (ATO) induction therapy in patients with low- and intermediate-risk APL. Methods: We retrospectively analyzed 224 newly diagnosed patients with low- and intermediate-risk APL who received single-agent ATO induction therapy. Early WBC kinetics and baseline clinical parameters were analyzed using least absolute shrinkage and selection operator regression and multivariate logistic regression to construct a nomogram. Results: DS occurred in 90 patients (40.2%), with a median onset time of 8 days (interquartile range, 7-11 days). WBC doubling occurred at a median of 3 days before DS onset, whereas the WBC peak occurred at a median of 2.5 days after DS onset. Rapid WBC proliferation and increased peripheral blood promyelocyte percentage were independent risk factors, whereas prolonged WBC doubling time was associated with reduced DS risk. The nomogram showed good discrimination, with an area under the curve of 0.825 (95% confidence interval, 0.770-0.880); the corrected area under the curve remained 0.817 after bootstrap internal validation. Conclusion: Early WBC kinetic characteristics provide time-sensitive indicators for DS risk assessment. This model may assist with early DS risk stratification and monitoring in low- and intermediate-risk APL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.